JPWO2023004308A5 - - Google Patents
Info
- Publication number
- JPWO2023004308A5 JPWO2023004308A5 JP2024503903A JP2024503903A JPWO2023004308A5 JP WO2023004308 A5 JPWO2023004308 A5 JP WO2023004308A5 JP 2024503903 A JP2024503903 A JP 2024503903A JP 2024503903 A JP2024503903 A JP 2024503903A JP WO2023004308 A5 JPWO2023004308 A5 JP WO2023004308A5
- Authority
- JP
- Japan
- Prior art keywords
- present
- gpa
- acid
- cancer
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223926P | 2021-07-20 | 2021-07-20 | |
| US63/223,926 | 2021-07-20 | ||
| PCT/US2022/073884 WO2023004308A1 (en) | 2021-07-20 | 2022-07-19 | Compositions and methods for inhibiting creatine transport as a treatment for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024528705A JP2024528705A (ja) | 2024-07-30 |
| JP2024528705A5 JP2024528705A5 (https=) | 2025-07-25 |
| JPWO2023004308A5 true JPWO2023004308A5 (https=) | 2025-07-25 |
Family
ID=84979767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503903A Pending JP2024528705A (ja) | 2021-07-20 | 2022-07-19 | がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240180912A1 (https=) |
| EP (1) | EP4373582A4 (https=) |
| JP (1) | JP2024528705A (https=) |
| AU (1) | AU2022316200A1 (https=) |
| CA (1) | CA3225305A1 (https=) |
| WO (1) | WO2023004308A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| CN116602948B (zh) * | 2023-06-06 | 2024-12-06 | 湖南岳靶生物医药有限公司 | 一种可用于降低膀胱癌细胞耐药性的化合物、组合物及其应用 |
| WO2025114580A1 (en) * | 2023-11-30 | 2025-06-05 | National And Kapodistrian University Of Athens | N-aminoguanidine derivatives with anticancer activity |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3736022A3 (en) * | 2012-10-31 | 2021-01-20 | The Rockefeller University | Treatment and diagnosis of colon cancer |
| US20180002702A1 (en) * | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| WO2021062157A1 (en) * | 2019-09-27 | 2021-04-01 | The Rockefeller University | Compositions and methods for treating metastatic gastrointestinal cancer |
| UA128683C2 (uk) * | 2019-10-22 | 2024-09-25 | Люпін Лімітед | Фармацевтична комбінація на основі інгібіторів prmt5 |
| JP2023505687A (ja) * | 2019-12-11 | 2023-02-10 | インスピルナ，インコーポレーテッド | 癌の処置方法 |
-
2022
- 2022-07-19 EP EP22846790.8A patent/EP4373582A4/en active Pending
- 2022-07-19 JP JP2024503903A patent/JP2024528705A/ja active Pending
- 2022-07-19 AU AU2022316200A patent/AU2022316200A1/en active Pending
- 2022-07-19 WO PCT/US2022/073884 patent/WO2023004308A1/en not_active Ceased
- 2022-07-19 CA CA3225305A patent/CA3225305A1/en active Pending
-
2024
- 2024-01-19 US US18/417,491 patent/US20240180912A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yamada et al. | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial | |
| JP7579465B2 (ja) | 頭頸部癌の治療のためのｅｇｆｒ阻害剤 | |
| Mauer et al. | Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus | |
| LoConte et al. | A multicenter phase 1 study of γ-secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors | |
| JP2019532051A5 (https=) | ||
| KR20180048804A (ko) | 바리티닙 및 항암제를 포함하는 병용 요법 | |
| TW201912158A (zh) | 在基於5-氟尿嘧啶的化療中[6r]-亞甲基四氫葉酸的多次推注施用 | |
| JPWO2022269525A5 (https=) | ||
| WO2018214925A1 (zh) | 用于治疗结直肠癌的喹啉衍生物 | |
| US20190105323A1 (en) | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake | |
| TWI752147B (zh) | [6r]-亞甲基四氫葉酸-在基於5-氟尿嘧啶的化療中有效的葉酸替代物 | |
| WO2025188668A1 (en) | Combination of a kras g12c inhibitor with an immune checkpoint inhibitor for the treatment of cancer | |
| WO2011092338A1 (en) | Combined treatment of pancreatic cancer with gemcitabine and masitinib | |
| Planchard et al. | A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS-or BRAF-mutant non-small cell lung cancer | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| EP1429713A2 (en) | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy | |
| AU2002330088A1 (en) | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy | |
| US20200138855A1 (en) | Novel antineoplastic drug based on specificity of cancer-cell metabolism | |
| JPWO2023004308A5 (https=) | ||
| JPWO2023009572A5 (https=) | ||
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| JPWO2022170060A5 (https=) | ||
| US9770462B2 (en) | Method of treating ovarian, tubal and peritoneal cancer | |
| Sawicka et al. | Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? | |
| CN111867591A (zh) | 治疗胆道癌的方法和组合疗法 |